SCHEMBL30223271

SCHEMBL30223271

COc1nccc2nccnc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
DRD1 P21728 1/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
USP2 O75604 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
CCR1 P32246 2/20 0.34
CCR5 P51681 2/20 0.34
CCR8 P51685 2/20 0.34
APLNR P35414 1/20 0.34
CCNB2 O95067 2/20 0.34
CDK1 P06493 2/20 0.34
CCNB1 P14635 2/20 0.34
GSK3A P49840 2/20 0.34
GSK3B P49841 2/20 0.34
CDK5 Q00535 2/20 0.34
CDK5R1 Q15078 2/20 0.34
CCNB3 Q8WWL7 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3483183 0.74 EGFR (0.41) ALDH1A1KDM4EMAPTCCR1CCR5
SCHEMBL607884 0.72 APLNR (0.40) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL30335572 0.72 MAPT (0.50) MEN1KMT2AALDH1A1KDM4EUSP2
SCHEMBL29463681 0.72 MAPT (0.50) MEN1KMT2AALDH1A1KDM4EUSP2
SCHEMBL87693 0.72 MAPT (0.50) MEN1KMT2AALDH1A1KDM4EUSP2
SCHEMBL30670488 0.71 LMNA (0.52) MEN1KMT2ADRD1KDM4EMAPT
SCHEMBL3793575 0.71 LMNA (0.52) MEN1KMT2ADRD1KDM4EMAPT
SCHEMBL30716827 0.70 MAPT (0.48) MEN1KMT2AALDH1A1KDM4EUSP2
SCHEMBL13271246 0.70 CCR1 (0.41) MEN1KMT2ADRD1ALDH1A1KDM4E
SCHEMBL31700880 0.69 MTNR1A (0.37) MEN1KMT2AALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230045421-A1 SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2023-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230045421-A1 SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME HAVCR2, HMBS, AHCY MEN1 1955/4885KMT2A 271/4885DRD1 4683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.